INTEL CORP

• HIGHShare count jumped 15% in a single year, from 4,330 million to 4,994 million shares S7. This came from multiple transactions: 275 million shares issued to the U.S. Department of Commerce at closing of the CHIPS Act deal, 159 million more shares held in escrow for future release, 87 million shares sold to SoftBank at $23/share for $2.0 billion, and 215 million shares sold to NVIDIA at $23.28/share for $5.0 billion S8. On top of that, warrants to purchase 241 million additional shares at $20/share were issued to the U.S. government (exercisable if Intel divests 51% or more of its foundry business) S8. Total net proceeds from stock issuances and warrants were $11.8 billion in 2025 S7. The company also has 117.5 million RSUs (restricted stock units, which are a form of employee pay that converts to shares) outstanding S9, plus $2.2 billion in unrecognized share-based compensation costs to be recognized over roughly 1.2 years S9. Existing shareholders have been significantly and repeatedly diluted, with more dilution embedded in the structure.

Nothing flagged.

• HIGHTotal debt stands at $47.2 billion in aggregate principal S6, against cash and short-term investments of $37.4 billion S4. Intel spent more on capital expenditures ($14.6 billion) than it generated in operating cash flow ($9.7 billion) in 2025 S7, producing adjusted free cash flow of negative $1.6 billion S4. The company was downgraded in August 2025 from BBB+ to BBB by a major rating agency, citing execution risk on the technology roadmap and delayed deleveraging S4. Debt maturities are manageable in the near term ($2.5 billion due in 2026, $3.8 billion in 2027) S9, but Intel also has $12.8 billion in committed capital expenditure obligations as of December 27, 2025 S9, plus $5.2 billion in remaining unfunded contributions to the Arizona SCIP (the joint manufacturing venture with Brookfield) S9. The combination of ongoing operating losses, large near-term spending commitments, and a downgraded credit rating makes the leverage picture genuinely strained.
• LOWThe Arizona SCIP joint venture carries a $5.6 billion construction-in-progress balance [S8

• HIGHThree customers (Dell, Lenovo, HP Inc.) represent 43% of net revenue in 2025, up from 40% in 2023 S6S7. The single largest customer is 19% of revenue, and two others are 12% each S7. Losing any one of these accounts would cause immediate, material revenue damage. Separately, China accounted for 24% of total revenue ($12.7 billion) in 2025 S7, and the U.S. government tightened export controls in 2025, requiring specific authorizations for sales to China S5. A further escalation in trade restrictions could cut off nearly a quarter of Intel's revenue.

• MEDIntel has had CEO transitions in 2019, 2021, 2024, and 2025, and "numerous unplanned senior management changes" are explicitly cited in the filing as creating disruption and loss of technical expertise S6. The current CEO, Lip-Bu Tan, was appointed in March 2025 S6. Frequent leadership churn at this level, in a company running two simultaneous transformation programs, is a meaningful execution risk even if no single departure is a crisis on its own.
• MEDThe U.S. government is now one of Intel's largest stockholders following the August 2025 CHIPS Act deal S5. The filing explicitly flags that government equity ownership "reduces other shareholders' voting influence and may limit future strategic transactions" S5. This is an unusual governance structure for a public company and creates potential conflicts between government policy objectives and shareholder value maximization.

• HIGHIntel has effectively lost the AI accelerator market to NVIDIA. Gaudi AI accelerator inventory write-offs totaled $375 million in 2025 and $922 million in 2024 S5. GPU competitors dominated AI data center spending "often at the expense of CPU investment" S2. Intel's own filing admits it was "unsuccessful in becoming a meaningful participant in the GPU accelerator market" S5. Meanwhile, AMD and ARM-based designs are eroding Intel's core CPU share. This is not a future risk; it is an ongoing revenue loss with no clear reversal in sight.

• HIGHIntel Foundry (the contract chip-making business) lost $10.3 billion in 2025, down from a $13.3 billion loss in 2024 S7. The business has "few external customers to date" S2. If Intel cannot win a significant external foundry customer, it has said it may pause or abandon its Intel 14A process node, and that decision could be effectively irreversible given the decades of investment required S5. The entire rationale for Intel's $100-plus billion in manufacturing assets depends on this business becoming viable. So far it is not.
• MEDThe Mobileye segment carries $8.2 billion in goodwill S6. Mobileye's market capitalization fell below its net asset carrying value in Q4 2025, which triggered a required quantitative impairment test S6. The test concluded no impairment was needed, but the margin is thin: the estimated fair value exceeded carrying value by less than 10%, and a 1% increase in the discount rate (the interest rate used to value future cash flows) would by itself trigger an $871 million impairment charge S4. Accumulated goodwill impairment losses already total $3.9 billion ($2.6 billion of that in Mobileye) S9.
• MEDIntel has $878 million in inventory reserves specifically for the Intel 18A process node ramp S4, on top of $11.6 billion in net inventory total S6. Supply constraints on Intel 7 and Intel 3 process nodes limited revenue in 2025 and are expected to persist into 2026 S4. Excess capacity charges, a fee Intel pays for manufacturing capacity it is not fully using, jumped 183% to $493 million in 2025 S7. High fixed costs in semiconductor manufacturing mean underutilization hits margins hard and quickly.

• MEDChina generated 24% of revenue ($12.7 billion) in 2025 S7, and U.S. export controls were expanded again in 2025 S5. Intel requires specific government authorizations for certain China sales. The filing also cites PFAS (a class of industrial chemicals facing tightening environmental regulation) restrictions that may require significant equipment investment and process modifications, with "limited technically feasible alternatives" S6. Israel operations include a leading-edge fabrication facility and Mobileye headquarters, with no war or political violence insurance S5.

• MEDVLSI Technology has an accrued liability of $1.0 billion on Intel's books S9. One Texas jury awarded VLSI $949 million (post-trial motions pending) and a separate Federal Circuit court affirmed a $1.5 billion infringement verdict S9. The Ireland SCIP arrangement carries a maximum liquidated damages (penalty for missing contractual milestones) exposure of $1.1 billion, of which $755 million has already been recognized S8. R2 Semiconductor obtained an injunction and recall order in a German court in February 2024 that could have disrupted Intel's European operations S6. Patent litigation from well-funded non-practicing entities (companies that hold patents purely for licensing or lawsuit purposes) is explicitly flagged as an escalating threat S6.

• HIGHThe effective tax rate was 98.3% in 2025 S4. Intel established a $9.9 billion valuation allowance (a valuation allowance means the company is saying it may not be able to use its tax deductions, so it writes them off) against U.S. deferred tax assets in Q3 2024 S4, and the valuation allowance grew by another $2.6 billion in 2025 S8. There is also a $1.5 billion long-term tax payable outstanding S8. The practical effect is that Intel cannot reliably reduce its tax bill using the losses it has accumulated, so reported earnings will be depressed even when operations improve.